I have one more example, and I think it's powerful. We have been working with an expert panel over the last number of months, and one of the things we're looking at is the monographs for all opioid drugs right now. As you would know, these are the labels that effectively tell practitioners what a drug can and can't be used for.
We're looking at whether it would be wise to add additional contraindications to monographs, which obviously would cause physicians, even for off-label use, to think twice about whether to use an opioid where doing so is definitely contraindicated. We'll be getting that expert advice shortly.
If we were to update product monographs for a large number of opioids, that obviously would involve a lot of work and a lot of expense, so again this is an area in which we might want to prioritize some of the funds the federal government receives for our regulatory system to actually have better labelling and better guidance to practitioners.